Printer Friendly

CircuLite[R] to Present Chronic Hemodynamic Data for Synergy[R] Micro-Pump for Chronic Heart Failure at American College of Cardiology Annual Scientific Session.

-Company to Participate in ACC Late-Breaking Session and Mechanical Support Symposium-

SADDLE BROOK, N.J. -- CircuLite([R]), Inc. today announced that Daniel Burkhoff, M.D., Ph.D., CircuLite's Chief Medical Officer and Adjunct Associate Professor of Medicine at Columbia University Medical School, will present an abstract detailing long-term hemodynamic data on the Synergy([R]) Pocket Micro-pump in a late-breaking session at the 58(th) Annual Scientific Session of the American College of Cardiology, held March 28-31 in Orlando, FL. Synergy is a micro-blood pump, the size of a AA battery, that can be implanted superficially in a "pacemaker-like" pocket. Synergy is the first and smallest device designed for partial circulatory support (up to 3L/min) and long-term use in patients with Class IIIb and early Class IV heart failure.

Abstract number 65205 is titled, "First Proof of Long-Term Hemodynamic Benefits of Partial Ventricular Support in Patients with Severe Heart Failure," and will be presented on Monday, March 30, 2009 from 8:15-8:25am EDT. The presentation will take place in Hall A2 of the Orange County Convention Center as part of session number 407, Late-Breaking Clinical Trials III - Emerging Technologies.

The Company is also participating in a Texas Heart Institute satellite symposium focused on mechanical support. This symposium, titled, "Heart Failure: Surgical and Interventional Breakthroughs in Current Practice," will take place on Saturday, March 28, 2009 from 8:00am - 12:00pm at The Peabody Hotel in Orlando, FL .

About Synergy([R])

The Synergy([R]) Pocket Micro-pump represents a new approach to mechanical circulatory support that can transform chronic heart failure management by providing a less-invasive, elective treatment option for patients before their disease state becomes emergent. Synergy is the first implantable system designed to provide partial circulatory support (PCS) for long-term use in millions of unserved patients that have NYHA Class IIIb/early IV disease.

CircuLite's patented micro-pump provides up to 3L/min of flow, which increases total cardiac output, offloads the heart, allowing it to rest, and potentially enables beneficial recovery of heart function. The size of a AA battery, the device is small enough to be implanted subcutaneously in a "pacemaker-like" pocket through a minimally-invasive procedure.

About CircuLite([R])

CircuLite is transforming heart failure treatment with the development of minimally-invasive devices for long-term partial circulatory support (PCS). By enabling a proactive and lower-risk treatment approach by supplementing a patient's native pumping capacity, CircuLite has the potential to improve the quality of life for millions of chronic heart failure patients and their families. CircuLite's pipeline of PCS devices is lead by the Synergy([R]) Pocket Micro-pump, the world's smallest implantable blood pump currently in a CE Mark clinical trial. Next-generation Synergy micro-pumps include an endovascular system, a fully-implantable system and a pediatric system. For more information on CircuLite and the Synergy Pocket Micro-pump devices, visit our website at www.CircuLite.net.

CAUTION: Investigational Device. Limited by Federal Law to Investigational Use Only.

CircuLite([R]) and Synergy([R]) are registered trademarks of CircuLite, Inc. in the United States.
COPYRIGHT 2009 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Mar 20, 2009
Words:498
Previous Article:Bryan Bergeron Wins HIMSS 2008 Book of the Year Award for 'Developing a Data Warehouse for the Healthcare Enterprise'.
Next Article:Ardea Biosciences to Present Preclinical Multi-Drug Combination Synergy Data on its Lead MEK Inhibitor, RDEA119, at the American Association for...
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters